DDNews: VeriStrat proves its prognostic capabilities

Posted on

“Biodesix announced in the third quarter of 2018 that in a study of samples from non-small cell lung cancer patients, the company’s VeriStrat test was found to be a significant predictor of outcomes (independent of ECOG Performance Status categories), patient EGFR mutation status, treatment received and other clinical variables.”

 

Read the full story.